Nesina Side Effects Not Linked To Cardiovascular Death Risk: Study
The findings of an new study indicate that the diabetes drug Nesina does not increase the risk of heart failure-related death in patients with acute coronary syndrome.
The findings of an new study indicate that the diabetes drug Nesina does not increase the risk of heart failure-related death in patients with acute coronary syndrome.
Onglyza and similar diabetes drugs may increase the risk of heart failure, according to an FDA warning that will lead to new label warnings being added to the drugs.
The FDA is warning that Januvia and similar diabetes drugs may be causing cases of severe joint pain among users.
Onglyza and several other drugs have been dropped from Express Scripts insurance coverage lists due to health concerns and the presence of safer, affordable alternatives.
Some diabetes drugs unexpected linked to heart failure risks, new report finds.
An FDA advisory panel has voted to add new label warnings to the diabetes drug Nesina.
An FDA advisory committee is calling on the agency to add new warning labels to the diabetes drug Onglyza, including warnings of risks of heart failure and death.
FDA reviewers warn that the diabetes drug Onglyza may increase the risk of death in some patients.
A look at diabetes drug adverse event reports suggests Nesina is the most dangerous and finds evidence of pancreatic cancer risks.
A new study appears to show that some diabetes drugs neither increase the risk of heart problems or prevent them.